Novartis
NEWS
Developed by Novartis, the drug, Tabrecta, is designed for a type of NSCLC that has spread to other parts of the body and cannot be removed by surgery.
Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted.
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
The COVID-19 pandemic is having a devastating effect on global business and biopharma companies are not excluded.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 20, 2020.
Swiss pharma giant Novartis will launch a Phase III trial assessing hydroxychloroquine for the treatment of COVID-19. The trial will be conducted across the United States.
Under the terms of the deal, Novartis is paying TScan an upfront technology access fee and research funding totaling $30 million.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
Novartis announced that, with Incyte, it is launching a Phase III clinical trial to determine if their cancer drug Jakavi (ruxolitinib) can be used to treat COVID-19.
JOBS
IN THE PRESS